Physician profile
Jonathan Slater
NPI 1992788160
$82,609.64
in general payments reported to CMS, 2019-2025
27 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $60.35 · 2021: $17K · 2022: $32K · 2023: $15K · 2024: $17K · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Travel and Lodging: $3,842 · Food and Beverage: $2,068 · Education: $25.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,223.50 |
| Travel and Lodging | $3,842.41 |
| Food and Beverage | $2,068.40 |
| Education | $25.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $64,179.00 | 2019-2024 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $14,319.05 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,908.47 | 2019-2021 | |
| Rockwell Medical, INC. | $850.00 | 2019 | |
| Travere Therapeutics, INC. | $169.40 | 2025 | Filspari |
| Medtronic, INC. | $140.59 | 2024 | Ellipsys Vascular Access System, Symplicity G3 |
| Mallinckrodt Hospital Products INC. | $138.18 | 2023-2025 | Acthar |
| Vifor Pharma, INC. | $117.77 | 2021-2023 | Veltassa |
| Daiichi Sankyo INC. | $115.68 | 2022 | |
| Alexion Pharmaceuticals, INC. | $108.72 | 2021-2025 | Ultomiris |
| Calliditas Therapeutics US INC. | $100.98 | 2024 | |
| Novo Nordisk INC | $51.44 | 2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $45.05 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.00 | 2024-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $44.32 | 2021-2024 | Givlaari |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $42.17 | 2019-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $32.22 | 2022-2024 | Nucala |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.80 | 2020 | |
| Scpharmaceuticals INC. | $24.00 | 2025 | |
| Cormedix INC. | $23.17 | 2024 | Defencath |
| Lexicon Pharmaceuticals, INC. | $23.13 | 2023 | Inpefa |
| Veloxis Pharmaceuticals, INC. | $20.71 | 2023 | Envarsus |
| One Lambda, INC. | $20.25 | 2024 | |
| Ardelyx, INC. | $19.98 | 2025 | Ibsrela |
| Genzyme Corporation | $18.08 | 2020 | |
| Amgen INC. | $15.30 | 2021 | |
| Aurinia Pharma U.S., INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Slater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.